Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Tidlig oppdagelse av utvalgte nevropatologier hos førere av motorvogner (NeuroDrive)

3. september 2026 oppdatert av: University Hospital Olomouc

Tidlig oppdagelse av utvalgte nevropatologier hos bilførere

Denne studien tar sikte på å utvikle tilgjengelige metoder for tidlig oppdagelse av utvalgte nevropatologier hos førere, med fokus på multippel sklerose og Parkinsons sykdom. Hovedmålet er å identifisere kliniske tester som korrelerer med resultater fra Vienna Test System (VTS), og dermed muliggjøre tidlig diagnostisering uten behov for komplekse nevrologiske eller nevropsykologiske vurderinger. Funnene kan forbedre effektiviteten av rutinemessige førerkontroller og informere fremtidige endringer i tsjekkisk trafikkregelverk for å øke trafikksikkerheten.

Studieoversikt

Status

Rekruttering

Detaljert beskrivelse

Studien vil bli gjennomført i to faser. Først vil en kohort med friske deltakere gjennomgå vurdering ved hjelp av Vienna Test System (VTS). Deretter vil en klinisk kohort bestående av personer diagnostisert med multippel sklerose (MS) eller Parkinsons sykdom (PD) bli rekruttert. Hver klinisk deltaker vil fullføre en grunnleggende nevrologisk undersøkelse, inkludert Montreal Cognitive Assessment (MoCA), 25-Foot Walk Test (25-FWT), Symbol Digit Modalities Test (SDMT) og Nine-Hole Peg Test (9-HPT). Deretter vil de gjennomgå VTS-testing.

Pasienter med PD vil bli klassifisert i henhold til Hoehn and Yahr-skalaen, mens de med MS vil bli stadieinndelt ved hjelp av Expanded Disability Status Scale (EDSS). Målet er å finne ut hvilke lett tilgjengelige kliniske tester som viser sterkest korrelasjon med VTS-resultater, og dermed identifisere pålitelige markører som kan inkorporeres i standard medisinske vurderinger av førere.

I den andre fasen vil parakliniske funn innhentet utenfor denne studiens omfang bli brukt til å styrke evidensgrunnlaget. Til syvende og sist søker prosjektet å foreslå en risikoligning i form av en praktisk kalkulator som leger kan bruke når de vurderer en pasients egnskap til å kjøre. Et ytterligere forventet resultat er utviklingen av målrettede kognitive og motoriske treningsintervensjoner for å hjelpe førere med nevropatologier med å opprettholde eller forbedre trygge kjøreevner.

Studietype

Observasjonsmessig

Registrering (Antatt)

200

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Olomouc Region
      • Olomouc, Olomouc Region, Tsjekkia, 779 00
        • Rekruttering
        • University Hospital Olomouc
        • Ta kontakt med:
        • Ta kontakt med:
          • Dalibor Zimek, M.D.
          • Telefonnummer: +420 702 048 036

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Pasienter fra poliklinisk behandling ved nevrologisk avdeling ved Universitetssykehuset Olomouc med full tilgang til parakliniske data og demografiske kjennetegn.

Beskrivelse

Inklusjonskriterier:

  • Person etter signert informert samtykke.
  • Etter å ha oppfylt gyldige diagnostiske kriterier for den gitte nevrologiske diagnosen.
  • Besittelse av gyldig førerkort og dokumentasjon på aktiv kjøring.
  • Aldersgrense 18 - 85 år.

Eksklusjonskriterier:

  • Påvist demensdiagnose basert på en aktuell psykologisk undersøkelse (MMSE 24 poeng eller mindre).
  • Diagnose av en sykdom eller tilstand som, i henhold til tsjekkisk lov nr. 277/2004 Coll., om medisinsk kjøreevne for motorkjøretøyer, endret (spesielt lov nr. 204/2025 Coll.), forhindrer eller betydelig begrenser evnen til å kjøre motorkjøretøy trygt (f.eks. demens, epilepsi, alvorlige bevissthetsforstyrrelser).
  • Alder under 18 år.
  • Alder over 85 år.
  • I den andre kohorten (pasienter med multippel sklerose), påvist og behandlet forverring de siste 6 ukene før inkludering i studien.
  • I MS-kohorten, nåværende EDSS > 6,5 poeng.
  • For PD-kohorten, nåværende Hoehn og Yahr-skår er større enn eller lik 4.
  • For begge kohorter, påvisning av parainfeksiøs forverring som demonstrert ved laboratorietesting.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Parkinson disease cohort
PD patients cohort will consist of 100 patients with parkinson disease aged between 18-85 years, with, with a balanced sex distribution to ensure representativeness and reduce gender bias. The target sample size (N = 100) has been chosen to provide adequate statistical power to detect moderate to strong correlations between clinical and paraclinical measures, it is intended to acquire a regular distribution across all age groups . Participants with premorbid cognitive impairment or those not clinically stable during the study period will be excluded, also participants with a Hoehn and Yahr stage greater than 4 will be excluded.
Multiple sclerosis cohort
Multiple sclerosis patient cohort will consist of 100 patients with multiple sclerosis. aged between 18-85 years, with, with a balanced sex distribution to ensure representativeness and reduce gender bias. The target sample size (N = 100) has been chosen to provide adequate statistical power to detect moderate to strong correlations between clinical and paraclinical measures, it is intended to acquire a regular distribution across all age groups. Participants with premorbid cognitive impairment or those not clinically stable during the study period will be excluded also an Expanded Disability Status Scale (EDSS) score above 6.5 will serve as an exclusion criterion.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Vienna Test Systems (VTS) - Determination Test (DT)
Tidsramme: Day 1

Vienna Test System (VTS) - Determination Test (DT). A computerized test of attention, stress tolerance, and psychomotor reactivity under complex conditions. Participants are presented with rapidly changing visual and auditory stimuli (e.g., colored lights, acoustic signals) and must respond as quickly as possible using multiple response keys or pedals.

Scoring: outcomes include mean and median reaction time (ms), number of correct responses, omission errors (missed stimuli), commission errors (incorrect responses), and measures of performance stability across the task. Faster, more accurate, and stable performance indicates better attentional control and stress tolerance.

Administration: conducted in a quiet environment with standardized VTS hardware and software. Trained staff provide uniform instructions and monitor performance.

Day 1
Vienna Test Systems (VTS) - Reaction Test (RT)
Tidsramme: Day 1

Vienna Test System (VTS) - Reaction Test (RT). A computerized assessment of simple and choice reaction time measuring perceptual speed and motor response. Participants are presented with visual and/or auditory stimuli and instructed to respond as quickly as possible by pressing a button (simple RT) or selecting the correct response among multiple options (choice RT).

Scoring: main outcomes include mean reaction time (ms), number of correct responses, and error rates. Faster and more accurate responses indicate better psychomotor speed and attention. Separate scores are calculated for simple and choice conditions.

Administration: conducted individually in a quiet, distraction-free environment using standardized VTS hardware and software. Trained staff provide standardized instructions and supervise.

Day 1
Vienna Test Systems (VTS) - Response inhibition (INHIB)
Tidsramme: Day 1

Vienna Test System (VTS) - Response Inhibition (INHIB). A computerized go/no-go paradigm measuring impulse control and inhibitory executive function. Participants are presented with a continuous sequence of visual stimuli on screen. They are instructed to respond via button press to "go" stimuli and withhold responses to "no-go" stimuli.

Scoring: main outcomes include reaction time to go-stimuli, number of correct responses (hits), commission errors (responses to no-go stimuli), and omission errors (missed go-stimuli). Higher accuracy with fewer commission errors reflects better inhibitory control.

Administration: conducted individually in a distraction-free environment using standardized VTS software and response panel. Trained staff provide instructions and supervise performance.

Day 1
Vienna Test Systems (VTS) - Vigilance/Sustained attention (WAFV) - Short version
Tidsramme: Day 1

Vienna Test System (VTS) - Vigilance/Sustained Attention (WAFV). A computerized test measuring sustained attention and vigilance. Participants monitor a continuous sequence of simple visual stimuli (e.g., small changes in geometric figures) presented at regular intervals. They are instructed to respond via button press whenever a predefined critical stimulus appears.

Scoring: main outcomes include number of correct detections (hits), omissions (missed targets), false alarms (incorrect responses), and reaction times. Higher hits and faster, stable reaction times indicate better vigilance; higher omissions or false alarms indicate poorer sustained attention.

Administration: conducted individually in a distraction-free environment using the standardized VTS software and response panel. Trained staff provide instructions and supervise.

Day 1

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Montreal Cognitive Assessment (MoCA)
Tidsramme: Day 1

Montreal Cognitive Assessment (MoCA). A clinician-administered screening tool for mild cognitive impairment covering multiple domains: attention, concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The test consists of 30 items with a maximum total score of 30; higher scores = better cognition. A score of 26 or above is considered normal. If the participant has ≤12 years of formal education, +1 point is added.

Administration: conducted face-to-face in a quiet environment by trained staff using validated language versions; completion requires ~10-15 minutes.

Outcomes: total score and change from baseline.

Day 1
25-Foot Walk Test (25-FWT)
Tidsramme: Day 1

25-Foot Walk Test (25-FWT). A quantitative measure of ambulatory function and walking speed. Participants are instructed to walk 25 feet (7.62 m) as quickly and safely as possible. Two trials are performed, typically with a short rest interval, and the average time (in seconds) is recorded using a stopwatch. Lower times = better mobility. Use of customary assistive devices (e.g., cane, walker) is permitted and documented.

Administration: conducted in a straight, unobstructed corridor with clearly marked start and finish lines. Trained staff provide standardized instructions and supervise for safety. Completion typically requires ~5 minutes.

Outcomes: average time to walk 25 feet (7.62 meters), ability to complete the test, and change from baseline.

Day 1
Symbol Digit Modalities Test (SDMT)
Tidsramme: Day 1

Symbol Digit Modalities Test (SDMT). A brief neurocognitive test of attention, processing speed, and visual scanning. Participants are shown a key pairing nine symbols with digits 1-9. Using this key, they write or orally state the digit corresponding to each symbol in a randomized sequence presented on the test form.

Scoring: the number of correct substitutions completed in 90 seconds is counted. Higher scores = better cognitive performance. Errors are recorded but not included in the raw score. Written and oral versions are available; the same mode is used across visits for consistency.

Administration: conducted in a quiet environment with standardized instructions, requiring ~5 minutes. Staff monitor to ensure task adherence.

Outcomes: total correct substitutions and standard deviation change from the normal value.

Day 1
Nine-Hole Peg Test (9-HPT)
Tidsramme: Day 1

Nine-Hole Peg Test (9-HPT). A standardized test of finger dexterity and fine motor function. Participants are instructed to place nine pegs into nine holes on a board, one at a time, as quickly as possible, and then remove them. Each hand is tested separately, typically with the dominant hand first, followed by the non-dominant hand.

Scoring: performance time (in seconds) for each hand is recorded with a stopwatch. Lower times = better dexterity. Two consecutive trials per hand are averaged. If a peg is dropped, the participant retrieves it and continues.

Administration: administered in a quiet environment by trained staff using standardized instructions. Completion time is usually 3-5 minutes for both hands.

Outcomes: mean completion time for each hand and change from baseline.

Day 1
Benton Visual Retention Test (BVRT)
Tidsramme: Day 1

A neuropsychological assessment of visual memory, perception, and visuoconstructive ability. Participants are shown a series of 10 geometric designs, each displayed for 10 seconds, and then asked to reproduce the design from memory using paper and pencil (Administration A). Alternate forms may be used to minimize practice effects.

Scoring: each reproduction is scored for number correct (maximum = 10) and for errors (e.g., omissions, distortions, rotations, perseverations, misplacements). Higher correct scores indicate better performance, while higher error counts indicate impairment.

Administration: conducted individually in a quiet setting by trained staff; typical completion ~15 minutes.

Outcomes: total correct responses, total errors, and change from baseline.

Day 1
The Big Five Inventory-2 Short Form (BFI-2-S)
Tidsramme: Day 1

Big Five Inventory-2 Short Form (BFI-2-S). A 30-item self-report assessing five personality domains: Extraversion, Agreeableness, Conscientiousness, Negative Emotionality, and Open-Mindedness. Items are rated on a 5-point Likert scale (1 = disagree strongly to 5 = agree strongly). For each domain, compute the mean of its 6 items after applying the manual's reverse-keying rules; higher scores = more of that trait. No total score is used.

Administration: validated language version via paper or secure ePRO; typical completion ~5-7 min. Staff provide standardized instructions and check completeness.

Outcomes: domain scores (1-5) and change from baseline. Timing: baseline and follow-ups within ±3 days of the visit window.

Day 1
Epworth Sleepiness Scale (ESS)
Tidsramme: Day 1

An 8-item self-report of daytime sleepiness. Participants rate their chance of dozing in common situations from 0 (would never doze) to 3 (high chance). Total score = sum of items (range 0-24; higher = worse sleepiness). Severity bands: 0-5 normal, 6-10 higher-than-normal, 11-12 mild, 13-15 moderate, 16-24 severe.

Administration: validated language version via paper or secure ePRO; typical completion ~2-3 min. Staff provide standardized instructions and check completeness before scoring.

Outcomes: total score; change from baseline; response = ≥3-point reduction from baseline; remission = score ≤10.

Day 1
Beck's Depression Inventory (BDI-II)
Tidsramme: Day 1
A 21-item self-report questionnaire assessing depressive symptoms over the past 2 weeks, including today. Each item is rated 0-3; total score ranges 0-63, with higher scores indicating more severe depression. Severity categories: 0-13 minimal, 14-19 mild, 20-28 moderate, 29-63 severe. The BDI-II is administered in validated language versions on paper or secure ePRO, requiring ~5-10 minutes. Staff provide standardized instructions and check completeness. Outcomes include total score, change from baseline, response (≥50% reduction from baseline), and remission (score ≤13).
Day 1
Driving experience self-evaluation questionnaire
Tidsramme: Day 1
This self-report questionnaire captures recent driving exposure and perceived difficulties over the past month. Items use 7-point Likert scales anchored "Never (1)" to "Every drive (7)". Content includes deliberate avoidance of challenging conditions (night driving, heavy traffic, bad weather, highways, unfamiliar routes), fatigue while driving, uncertainty in traffic situations (e.g., speed limits, lane selection, right of way), perceived complexity/overload, inattention, vehicle-control errors (e.g., wrong gear, pedal mix-ups), oversight errors (e.g., missed lights/signs, failure to check mirrors), warnings from other road users, risk-taking, traffic-rule violations, and emotional arousal during driving. A brief exposure module records typical driving frequency, lifetime kilometers, and the frequency of driving in specific conditions. Higher scores indicate more frequent difficulties; the primary metric is the mean item score (1-7).
Day 1

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. mai 2026

Primær fullføring (Antatt)

31. desember 2026

Studiet fullført (Antatt)

31. desember 2028

Datoer for studieregistrering

Først innsendt

13. januar 2026

Først innsendt som oppfylte QC-kriteriene

13. januar 2026

Først lagt ut (Faktiske)

22. januar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

8. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • OP JAK ITI VZ 1
  • CZ.02.01.01/00/23_021/0008829 (Annet stipend/finansieringsnummer: Operational Programme Jan Ámos Komenský financed by the European Union (EU) and the State Budget of Czech Republic)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere